Take Charge干预用于卒中后患者的经济学分析:随机试验结果
本研究基于TaCAS随机试验,对400例急性卒中后出院至社区非机构生活的成人进行经济学分析,比较Take Charge干预(1或2次会话)与对照干预的成本效果。结果显示Take Charge组1年护理成本更低,健康效用评分更高,每获得一个QALY的成本为负值,敏感性分析证实其具有成本效果。
要点
- Take Charge干预组1年护理成本较对照组低1412美元(95%CI -3553至+729)。
- Take Charge组健康效用评分0.75,对照组0.71,差值0.04(95%CI 0.0-0.08)。
- 每获得一个QALY的成本为-35296美元,在5000美元/QALY阈值下具有成本效果的概率为99%。
核心结论
- Take Charge干预具有成本效果,且可能节省成本。
研究设计与样本
- 开放、平行组、随机试验,比较主动干预与对照干预,采用盲法结局评估。
- 共纳入400例急性卒中后出院至社区非机构生活的成人。
主要发现
- Take Charge组1年护理成本均值为4706美元(95%CI 3758-6014),对照组为6118美元(95%CI 4350-8005),均值差为-1412美元(95%CI -3553至+729)。
- Take Charge组健康效用评分均值为0.75(95%CI 0.73-0.77),对照组为0.71(95%CI 0.67-0.75),均值差为0.04(95%CI 0.0-0.08)。
- 每获得一个QALY的成本为-35296美元(=-25524英镑,=-30019欧元)。
关键数值与推荐
- 敏感性分析证实Take Charge在极低支付意愿阈值下仍具有成本效果。
- 在5000美元/QALY阈值下,Take Charge具有成本效果的概率为99%。
临床怎么用
- 对于急性卒中后出院至社区生活的成人,可考虑采用Take Charge这一优势取向、自我导向的康复干预以降低护理成本并改善健康效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To undertake an economic analysis of the Take Charge intervention as part of the Taking Charge after Stroke (TaCAS) study. DESIGN: An open, parallel-group, randomised trial comparing active and control interventions with blinded outcome assessment. SETTING: Community. PARTICIPANTS: Adults (n = 400) discharged to community, non-institutional living following acute stroke. INTERVENTIONS: The Take Charge intervention, a strengths based, self-directed rehabilitation intervention, in two doses (one or two sessions), and a control intervention (no Take Charge sessions). MEASURES: The cost per quality-adjusted life year (QALY) saved for the period between randomisation (always post hospital discharge) and 12 months following acute stroke. QALYs were calculated from the EuroQol-5D-5L. Costs of stroke-related and non-health care were obtained by questionnaire, hospital records and the New Zealand Ministry of Health. RESULTS: One-year post hospital discharge cost of care was mean (95% CI) $US4706 (3758-6014) for the Take Charge intervention group and $6118 (4350-8005) for control, mean (95% CI) difference $ -1412 (-3553 to +729). Health utility scores were mean (95% CI) 0.75 (0.73-0.77) for Take Charge and 0.71 (0.67-0.75) for control, mean (95% CI) difference 0.04 (0.0-0.08). Cost per QALY gained for the Take Charge intervention was $US -35,296 (=£ -25,524, € -30,019). Sensitivity analyses confirm Take Charge is cost-effective, even at a very low willingness-to-pay threshold. With a threshold of $US5000 per QALY, the probability that Take Charge is cost-effective is 99%. CONCLUSION: Take Charge is cost-effective and probably cost saving.
引用
- Te Ao B, Harwood M, Fu V, et al. Economic analysis of the 'Take Charge' intervention for people following stroke: Results from a randomised trial. Clin Rehabil. 2021. PMID: 34414801. doi:10.1177/02692155211040727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。